Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Pathology

Internal Medicine

Gastroenterology

Genetics

Show all topics

DOI

10.1016/s0140-6736(16)32537-5